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BACKGROUND: Continuing antiplatelet therapy (APT) has been generally recommended during noncardiac surgery, but it is 
uncertain if preoperative discontinuation of APT has been avoided or harmful in patients with second- generation drug- eluting 
coronary stents.
METHODS AND RESULTS: Patients undergoing noncardiac surgery after second- generation drug- eluting coronary stent implan-
tation were assessed in a multicenter cohort in Korea. Net adverse clinical events within 30 days postoperatively, defined as 
all- cause death, major adverse cardiac events, and major bleeding, were evaluated. Of 3582 eligible patients, 49% patients 
discontinued APT during noncardiac surgery. The incidence of net adverse clinical events was comparable between patients 
with continuation versus discontinuation (4.1% versus 3.4%; P=0.257) of APT during noncardiac surgery. Perioperative discon-
tinuation of APT did not impact on net adverse clinical events (adjusted hazard ratio [HR], 1.00; 95% CI, 0.69–1.44; P=0.995). 
In subgroup analysis, patients undergoing intra- abdominal surgery were exposed to less risk of major bleeding by discontinu-
ing APT (adjusted HR, 0.26; 95% CI, 0.08–0.91; P=0.035). Prolonged discontinuation of APT for ≥9 days was associated with 
higher risk of a major adverse cardiac event compared with continuing APT (adjusted HR, 3.38; 95% CI, 1.36–8.38; P=0.009).
CONCLUSIONS: APT was discontinued preoperatively in almost half of patients with second- generation drug- eluting coronary 
stents. Our explorative analysis showed that there was no significant impact of discontinuing APT on the risk of perioperative 
adverse events except that discontinuing APT may be associated with decreased hemorrhagic risk in patients undergoing 
intra- abdominal surgery.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT03908463.
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Second- generation drug- eluting stents (DESs) re-flect technological improvements to provide better efficacy and safety, with a lower risk of restenosis 
and stent thrombosis after percutaneous coronary 
intervention (PCI).1,2 Continuous antiplatelet therapy 
(APT) is important to prevent ischemic events following 
PCI3–5; however, platelet inhibition increases the risk of 
hemorrhage, especially during invasive procedures.
In patients with DESs, clinicians must decide 
whether to continue or discontinue APT before 
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noncardiac surgery (NCS) to achieve the appropri-
ate balance between thromboembolic and bleed-
ing risks. In the POISE- 2 (Perioperative Ischemic 
Evaluation 2) randomized trial, continuing aspirin did 
not reduce ischemic events and increased bleeding 
risk in patients overall,6 but a secondary analysis 
demonstrated an association between aspirin use 
and lower ischemic risk after NCS among patients 
with previous PCI.7 Conversely, a large population- 
based cohort study of patients with previous PCI 
reported no reduction of ischemic events with con-
tinuing APT perioperatively.8 Nevertheless, continu-
ing APT is widely regarded as optimal perioperative 
management in patients undergoing NCS without 
excessive bleeding risk, for which prompt discon-
tinuation of all antiplatelet agents, including aspirin 
and P2Y12 inhibitors, may also be considered.6,8 
Evidence is especially limited regarding continuation 
or discontinuation of APT in patients with second- 
generation DESs undergoing NCS. The objectives of 
this study were to describe patterns of perioperative 
APT in this setting and to evaluate whether discontin-
uing APT is safe in patients with second- generation 
DESs.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Design and Population
We used data from a prospective multicenter cohort 
registry (KOMATE [Korean Multicenter Angioplasty 
Team registry]; NCT03908463), which collects infor-
mation regarding all patients undergoing PCI at major 
medical centers in Korea. The registry records include 
demographic, anatomic, and procedural characteris-
tics, and postprocedure clinical outcomes. Nine cent-
ers participated in this study. Among 41 083 patients 
with a second- generation DES in 9 institutes, we iden-
tified 3791 who underwent NCS from May 2008 to 
October 2018. We included 3582 patients in the final 
analysis, after excluding those undergoing emergency 
surgery, which should not be delayed >3 days since 
initial decision (n=87), receiving anticoagulants without 
an antiplatelet agent (n=55), with life- threatening condi-
tions at the time of surgery (n=33), missing critical data 
(n=15), and lost to follow- up (n=12), as well as those 
who underwent coronary artery bypass graft (n=6) 
or heart transplantation (n=1) before NCS (Figure 1). If 
patients underwent >1 NCS after second- generation 
DES implantation, we considered only the first opera-
tion in our analyses. Investigators at each study site 
collected the medical records regarding surgery- 
related variables and cessation of antiplatelet agents. 
The institutional review board at each site approved 
the study protocol and waived the need for informed 
consent. We followed the Strengthening the Reporting 
of Observational Studies in Epidemiology reporting 
guidelines.9
End Points
We primarily assessed clinical outcomes within 
30  days post- NCS, including death and adverse 
cardiac and hemorrhagic events. Net adverse clini-
cal event (NACE) was defined as a composite of all- 
cause death, major adverse cardiac event (MACE), 
and major bleeding. MACE included cardiac death, 
myocardial infarction (MI), and stent thrombosis. 
Cardiac death was defined as death with ischemic 
symptoms, typical electrocardiographic ischemic 
CLINICAL PERSPECTIVE
What Is New?
• Among patients undergoing noncardiac sur-
gery after second-generation drug-eluting stent 
implantation, preoperative discontinuation of 
antiplatelet therapy was common and safe in 
terms of both ischemic and hemorrhagic risk.
• Discontinuing APT may be associated with 
lower risk of major bleeding in the certain types 
of surgery (eg, intra-abdominal) compared with 
continuing antiplatelet therapy in patients with 
second-generation drug-eluting stents.
What Are the Clinical Implications?
• Our study supports the notion that discontinu-
ing antiplatelet therapy may be considered an 
acceptable option for patients undergoing cor-
onary revascularization with second-generation 
drug-eluting stents before noncardiac surgery 
unless unduly prolonged (≥9 days).
Nonstandard Abbreviations and Acronyms
APT  antiplatelet therapy
DAPT  dual antiplatelet therapy
DES  drug-eluting stent
HR  hazard ratio
MACE  major adverse cardiac event
MI  myocardial infarction
NACE  net adverse clinical event
NCS  noncardiac surgery
PCI  percutaneous coronary intervention
POISE-2 Perioperative Ischemic Evaluation 2
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patterns, cardiac enzyme elevation, or fatal ventric-
ular arrhythmia with no obvious noncardiac cause 
of death. MI was defined according to the Third 
Universal Definition as an increase in creatine kinase 
myocardial band fraction above the upper limit of nor-
mal or an increase in troponin- T or - I above the 99th 
percentile of the upper limit of normal and ≥1 of the 
following: symptoms, electrocardiographic changes, 
or imaging or angiographic findings indicative of 
MI.10 Stent thrombosis was defined according to 
the Academic Research Consortium recommenda-
tions.11 Major bleeding was defined according to the 
International Society of Thrombosis and Hemostasis 
(available in Data S1).12 Each event was independently 
adjudicated by 2 investigators (CK, HK). In a case of 
disagreement, a third investigator (J- SK) reviewed it 
to provide final adjudication. Two independent ad-
judications showed 88% agreement and k=0.75 for 
classification of cardiac death.
Revascularization, APT, and Surgical Risk
All patients underwent PCI according to each par-
ticipating site’s standard protocol. Second- generation 
DES included durable polymer everolimus- and 
zotarolimus- eluting stents; biodegradable polymer 
everolimus- , biolimus- , and sirolimus- eluting stents; 
and polymer- free biolimus- eluting stents. All patients 
received dual APT (DAPT) with aspirin and P2Y12 in-
hibitor at discharge after PCI. High- risk PCI was defined 
as the presence of ≥1 risk factors, including left main 
stenting, 3 stents or long total stent length (≥60 mm), 
small- diameter stent (<2.5 mm), 2 stents at bifurcation, 
or chronic total occlusion.13,14 All study sites share a 
policy of consensus decision for perioperative APT be-
fore NCS in patients with previous PCI. Cardiologists 
recommended whether each antiplatelet agent should 
be continued or discontinued for a certain period of 
time before NCS. Surgeons and anesthesiologists fi-
nally decided and recorded the duration of APT dis-
continuation before NCS. Investigators reviewed 
medical records to confirm the discontinuation dura-
tion for antiplatelet drugs. Patients who were guided to 
withdraw all antiplatelet agents for ≥1 days were clas-
sified as discontinuing APT, and prescription patterns 
of continuing APT were subsequently categorized into 
aspirin monotherapy, P2Y12 inhibitor monotherapy, 
and DAPT. Urgent surgery was defined as if surgery 
should be performed within 30  days for a condition 
that has the potential to deteriorate quickly and be-
come an emergency.15 Cardiac risk of each NCS was 
classified as low (<1%) or intermediate to high (≥1%), 
according to ≈30- day risk of cardiovascular death or 
MI.4,16 Hemorrhagic risk of each NCS was categorized 
into 3 groups (low, intermediate, or high), according to 
Rossini et al.14
Statistical Analysis
Continuous variables were reported as median and 
quartiles and compared using Mann–Whitney U 
test. Categorical variables were reported as number 
and percentage and compared using chi- square or 
Fisher’s exact tests. A multivariate logistic regres-
sion model was used to identify independent fac-
tors associated with discontinuing APT by backward 
Figure 1. Flow diagram of study participants. 
CABG indicates coronary artery bypass graft; DES, drug- eluting stent; NCS, noncardiac surgery; and PCI, percutaneous coronary 
intervention.
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elimination, which first included significant covariates 
identified by univariate analysis, and the final model 
including significant covariates was diagnosed by 
McFadden’s R2 statistics. Fit of the model was con-
firmed by using the likelihood- ratio test comparing 
with reduced model deleting each single covariate.17 
Kaplan–Meier estimate and the log- rank test were 
used to depict cumulative incidences of adverse 
events,18 and the Cox proportional hazards model 
was used to compare the hazard of each adverse 
event between APT strategies, adjusting for potential 
confounders, which included explanatory variables 
finally chosen in a parsimonious multivariate model 
by backward stepdown deletion of covariates with 
the least significant variables and comparison of 
Akaike information criterion (Tables S1 through S3, 
Figure S1). Covariates associated with NACE, MACE, 
and major bleeding were applied to control for con-
founding in each subgroup model. Diabetes mel-
litus, chronic heart failure, chronic kidney disease, 
anemia, high- risk PCI, preoperative DAPT and β- 
blocker, urgent surgery, and surgery risk for cardiac 
and hemorrhagic event were adjusted for multivari-
ate models for NACE. Chronic heart failure, anemia, 
use of β- blocker, high- risk PCI, duration between 
PCI and surgery, urgent surgery, and cardiac risk of 
surgery adjusted for multivariate models for MACE. 
Body mass index, anemia, urgent surgery, and hem-
orrhagic risk of surgery were applied for adjustment 
of multivariate models for major bleeding. Subgroup 
analyses were performed according to variable con-
ditions associated with patient, procedure, surgery- 
related risk factors, and each type of surgery. For the 
analysis, particular types of surgery including oph-
thalmologic, spinal, head and neck, intrathoracic, 
gynecologic, breast, and transplantation surgeries 
were combined because adverse events occurred in 
fewer than 10 patients undergoing each surgery. A 
generalized additive model was applied to describe 
the nonparametric association between NACE and 
duration of APT discontinuation by using the “mgcv” 
package in R statistical software.19 After duration 
of APT discontinuation for the least risk for NACE 
was determined by the nonparametric smoothing 
plot, different durations of discontinuation were cat-
egorized and compared with continuing APT and 
continuing aspirin monotherapy in regard to clinical 
outcomes. The multiple imputation by chained equa-
tion approach was used to impute missing values. 
We generated 5 complete data sets and pooled the 
coefficients of subsequent analyses.20 Two- sided 
tests were performed, and P<0.05 was considered 
statistically significant. All statistical analyses were 
performed using R statistical software (version 3.5.2; 
R Foundation for Statistical Computing, Vienna, 
Austria).
RESULTS
Patterns of Perioperative APT
Of the 3582 eligible patients, 1832 (51%) contin-
ued APT and 1750 (49%) discontinued APT before 
NCS (Figure 1). The baseline characteristics of the 2 
groups are shown in Table 1. Incidence of discontinu-
ing APT widely differs across types of surgery. More 
patients discontinued APT before certain type of 
surgeries including gynecology (79%), breast (70%), 
head and neck (63%), and intra- abdominal (62%) 
surgeries; however, only some of the candidates 
for vascular (15%) or ophthalmologic (27%) surger-
ies discontinued APT. In women, preoperative use of 
aspirin monotherapy, β- blocker, or renin- angiotensin 
system inhibitor and surgery with higher cardiac or 
hemorrhage risk were independently associated with 
discontinuing APT. Chronic kidney disease, stable an-
gina, high- risk PCI, and urgent surgery were related 
to discontinuing APT (Table 1, Table S4). Seventy- five 
percent of patients undergoing NCS within 6 months 
after PCI preoperatively continued APT, while 44% 
of patients undergoing NCS 12  months after PCI 
continued APT. Compared with other patterns of 
perioperative APT, continuing DAPT was associated 
with higher incidence of risk factors, including dia-
betes mellitus, chronic heart failure, chronic kidney 
disease, anemia, MI, and high- risk PCI (Table S5). 
Median time interval between PCI and NCS in pa-
tients continuing DAPT (7 months) was much shorter 
than the other groups (23–27  months; Table S5). 
Median duration of DAPT was 10.3  months in pa-
tients with stable angina and 11.2 months in patients 
with acute coronary syndrome.
Incidence and Risk of Perioperative 
Adverse Events
Perioperative NACE, MACE, and major bleeding oc-
curred in 135 (3.8%), 40 (1.1%), and 97 (2.7%) patients, 
respectively. There were no significant differences in 
the incidence of NACE (4.1% versus 3.4%; P=0.257), 
MACE (1.4% versus 0.8%; P=0.109), and major 
bleeding (2.6% versus 2.9%; P=0.664) between 
continuation versus discontinuation of APT, respec-
tively (Figure 2, Table S6). Adjusted hazard ratio (HR) 
of discontinuing APT was 1.00 (95% CI, 0.69–1.44; 
P=0.995) for NACE and 1.22 (95% CI, 0.80–1.87; 
P=0.349) for major bleeding (Table 2). Discontinuing 
APT tended to lead to a lower incidence of MACE 
compared with continuing APT (0.8% versus 1.4%; 
unadjusted HR, 0.56; 95% CI, 0.29–1.07; P=0.081). 
However, discontinuing APT did not have an inde-
pendent effect on MACE in adjusted analysis (HR, 
1.13; 95% CI, 0.57–2.24; P=0.721). Anemia, urgency, 
and surgical risk had independent influences on 
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Table 1. Baseline Patient and Surgical Characteristics
Covariates Continuation (N=1832) Discontinuation (N=1750) P Value
Age, y 69 (61–75) 69 (61–75) 0.06
Male 1282 (70) 1120 (64) <0.001
BMI, kg/m2* 24.4 (22.5–26.6) 24.4 (22.2–26.4) 0.07
Comorbidity
Hypertension 1384 (76) 1304 (75) 0.50
Diabetes mellitus 871 (48) 768 (44) 0.03
Chronic heart failure 192 (10) 145 (8) 0.03
Chronic kidney disease 365 (20) 182 (10) <0.001
Prior cerebrovascular attack 218 (12) 184 (11) 0.21




Aspirin 627 (34) 610 (35)
Clopidogrel 215 (12) 336 (19)
Ticagrelor 6 (0) 2 (0)
Prasugrel 0 (0.0) 1 (0)
Others 0 (0.0) 5 (0)
Dual therapy 984 (54) 796 (45)
Duration of discontinuation before 
surgery, d
··· 5 (4–7) ···
Oral anticoagulant 6 (0) 12 (1) 0.20
β- Blocker 802 (44) 853 (49) 0.003
Calcium channel blocker 565 (31) 576 (33) 0.20
RAS inhibitor 843 (46) 926 (53) <0.001
Percutaneous coronary intervention
Diagnosis at revascularization <0.001
Stable angina 893 (49) 708 (40)
Unstable angina 443 (24) 547 (31)
Myocardial infarction 496 (27) 495 (28)
Stented vessel
Left main 133 (7) 75 (4) <0.001
Left anterior descending artery 1107 (60) 1095 (63) 0.20
Left circumflex artery 462 (25) 466 (27) 0.36
Right coronary artery 641 (35) 621 (35) 0.78
Type of DES
Durable polymer 1210 (66) 1353 (77) <0.001
Bioresorbable polymer 618 (34) 409 (23) <0.001
Polymer- free 70 (4) 18 (1) <0.001
Number of stents 0.001
1 1087 (59) 1036 (59)
2 453 (25) 501 (29)
≥3 292 (16) 213 (12)
Maximum stent diameter, mm* 3.0 (3.0–3.5) 3.0 (3.0–3.5) 0.05
Total stent length, mm* 30 (18–51) 30 (18–48) 0.83
High- risk PCI 484 (26) 393 (22) 0.007
Noncardiac surgery
Duration from PCI, mo 16 (5–37) 23 (12–41) <0.001
 (Continued)
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NACE, MACE, and major bleeding. Chronic heart fail-
ure, nonuse of β- blocker, and high- risk PCI were in-
dependent predictors for NACE and MACE (Table 2). 
Shorter duration between PCI and NCS was as-
sociated with increased risk of MACE in univariate 
analysis. NCS <6  months after PCI also tended to 
increase ischemic risk after adjustment (HR, 1.99; 
95% CI, 0.98–4.01; P=0.056). However, the risk of 
major bleeding was not significantly affected by the 
post- PCI duration (Table  2). Risk of discontinuing 
APT was not significant for NACE, MACE, and major 
bleeding in subgroups (Figure 3, Figures S2 and S3) 
However, the effect of discontinuing APT widely dif-
fered across different types of surgeries. In patients 
undergoing intra- abdominal surgery, discontinuing 
APT tended to be beneficial in terms of NACE (ad-
justed HR, 0.40; 95% CI, 0.15–1.08; P=0.070), which 
was mainly driven by a reduction in major bleeding 
(adjusted HR, 0.26; 95% CI, 0.08–0.91; P=0.035). 
When continuing APT categorized into aspirin, P2Y12 
inhibitor monotherapy, and DAPT, incidence of NACE 
was not significantly different among the 3 groups 
and patients who discontinued APT. However, pa-
tients continued DAPT had the highest incidence 
of all- cause death (3.8% versus 1.1–1.4%; P<0.001) 
and MACE (2.8% versus 0.8%; P=0.008) than other 
groups (Table S7).
Duration of Antiplatelet Therapy 
Discontinuation and Perioperative 
Adverse Events
Because a nonparametric smoothing plot indicated 
that discontinuing APT for 6 days was associated with 
the lowest risk of NACE in patients undergoing NCS, 
an interval of 4 to 8 days for discontinuing APT would 
be optimal for the least risk for NACE (Figure S4). In uni-
variate analysis, discontinuing APT for 4 to 8 days was 
associated with the lowest risk for NACE (unadjusted 
HR, 0.59; 95% CI, 0.39–0.92; P=0.019) and MACE (un-
adjusted HR, 0.12; 95% CI, 0.03–0.52; P=0.004) com-
pared with continuing APT (Figure 4). After adjustment, 
Covariates Continuation (N=1832) Discontinuation (N=1750) P Value
<6 491 (27) 181 (10) <0.001
6 to <12 290 (16) 252 (14)
≥12 1051 (57) 1317 (75)
Urgent surgery 281 (15) 88 (5) <0.001
Risk of cardiac event <0.001
Low (<1%) 1082 (59) 892 (51)
Intermediate to high (≥1%) 750 (41) 858 (49)
Risk of hemorrhage <0.001
Low 1268 (69) 896 (51)
Intermediate to high 425 (23) 654 (37)
High 139 (8) 200 (11)
Type <0.001
Orthopedic 276 (15) 358 (20)
Superficial 324 (18) 301 (17)
Ophthalmologic 403 (22) 147 (8)
Intra- abdominal 198 (11) 317 (18)
Urologic 183 (10) 207 (12)
Vascular 210 (11) 37 (2)
Spinal 82 (4) 129 (7)
Head and neck 51 (3) 87 (5)
Intrathoracic 26 (1) 37 (2)
Gynecologic 12 (1) 46 (3)
Intracranial 49 (3) 65 (4)
Breast 6 (0) 14 (1)
Transplantation 12 (1) 5 (0)
Data are median (interquartile range) or number (percentage). BMI indicates body mass index; DES, drug- eluting stent; PCI, percutaneous coronary 
intervention; and RAS, renin- angiotensin system.
*These comparisons were performed among patients without missing values (values were missing for hemoglobin in 517 patients, BMI in 77 patients, stent 
diameter in 4 patients, and total stent length in 3 patients).
Table 1. Continued
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prolonged discontinuation of APT for ≥9  days led to 
higher risk of MACE compared with continuing APT 
(adjusted HR, 3.38; 95% CI, 1.36–8.38; P=0.009) or 
aspirin monotherapy (adjusted HR, 4.57; 95% CI, 1.44–
14.5; P=0.010), however, discontinuation for ≤8  days 
was similar to continuing APT or continuing aspirin 
monotherapy in terms of the risk of NACE, MACE, and 
major bleeding (Figure S5).
DISCUSSION
Our study demonstrated that discontinuation of APT 
was presented in almost half of patients with second- 
generation DESs before NCS. Discontinuing APT was 
more frequent as surgical risk for cardiac or hemor-
rhagic risk increased. It was not of importance for 
the risk of NACE, MACE, and major bleeding in over-
all patients; however, it led to less major bleeding in 
intra- abdominal surgery. Prolonged discontinuation 
of APT for ≥9 days seemed to be associated with in-
creased risk of MACE than continuing APT or aspirin 
monotherapy.
Current guidelines have stressed continuing APT 
during NCS. According to 2014 European Society 
of Cardiology/European Society of Anaesthesiology 
guidelines regarding NCS, continuing aspirin or a 
P2Y12 inhibitor may be recommended for surgery 
within 3 to 12 months of DES implantation, although 
discontinuing aspirin is another option if difficult he-
mostasis is anticipated.4 The 2014 American College 
of Cardiology/American Heart Association guidelines 
regarding NCS also recommended that patients with 
coronary stents continue aspirin during NCS, if pos-
sible.3 However, no firm evidence supports maintain-
ing antiplatelet therapy; thus, both guidelines contain 
a proviso that the decision to continue or discontinue 
APT should be based on weighing the risks of bleeding 
and stent thrombosis in each individual.
Multidisciplinary approaches regarding periop-
erative APT during NCS have suggested classifying 
thrombotic and hemorrhagic risks for each type of 
surgery, type of coronary stent, and clinical and an-
giographic characteristics. While this is reasonable in 
usual situations, it remains unclear whether continu-
ing aspirin is preferred for patients with a second- 
generation DES.14 Indeed, predicting bleeding or 
ischemic events or comparing risk levels is difficult 
because high cardiac risk is frequently linked to an in-
creased bleeding risk, and many instances of periop-
erative bleeding, stent thrombosis, and MI occur 
unpredictably. The reduced risk of ischemic events 
following PCI with second- generation DES is also 
relevant: These stents are associated with a lower 
risk of MI and stent thrombosis than first- generation 
DES2 and bare- metal stents.1 Accordingly, continuing 
APT may be less necessary with second- generation 
DESs in those with previous stents. Although a cardi-
ologist may recommend continuing APT to minimize 
ischemic events, a surgeon may recommend dis-
continuation, especially in the presence of clinical or 
surgical factors increasing hemorrhagic risk, which 
would commonly increase cardiac risk as well. Thus, 
decisions should be individualized while consider-
ing various clinical factors. Practical methods of risk 
stratification or comprehensive discussion should be 
explored to optimize perioperative APT to minimize 
both ischemic and bleeding risks.
Discontinuing APT was more common in interme-
diate or high- cardiac- risk surgery, which was contrary 
to our expectations and previous recommendations for 
continuing APT based on the cardiac risk of surgery. 
Cardiac risk factors including chronic kidney disease, 
Figure 2. Cumulative incidence of perioperative adverse events comparing continuation vs discontinuation of antiplatelet 
therapy.
Net adverse clinical event (A), major adverse cardiac event (B), and major bleeding (C).
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Table 2. Predictors of Net Adverse Clinical Event, Major Adverse Cardiac Event, and Major Bleeding After Noncardiac 
Surgery
Predictors
Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Net adverse clinical events
Discontinuing antiplatelet therapy 0.81 (0.58–1.14) 0.228 1.00 (0.69–1.44) 0.995
Age, per 1- y increase 1.03 (1.01–1.04) 0.006 ··· ···
BMI, per 1- kg/m2 increase 0.94 (0.89–0.99) 0.014 ··· ···
Diabetes mellitus 1.58 (1.13–2.23) 0.008 1.36 (0.95–1.95) 0.094
Chronic heart failure 2.10 (1.35–3.26) 0.001 1.63 (1.03–2.57) 0.038
Chronic kidney disease 2.04 (1.40–2.99) <0.001 1.53 (0.99–2.37) 0.058
Anemia 2.71 (1.92–3.83) <0.001 1.89 (1.28–2.79) 0.001
High- risk PCI 1.67 (1.17–2.38) 0.005 1.54 (1.08–2.21) 0.017
Preoperative medication
DAPT 1.77 (1.18–2.64) <0.001 1.42 (0.94–2.14) 0.096
β- Blocker 0.73 (0.51–1.03) 0.073 0.68 (0.48–0.96) 0.030
Duration between PCI and surgery, mo
<6 1.68 (1.13–2.50) 0.010 ··· ···
6 to <12 1.33 (0.83–2.11) 0.235 ··· ···
≥12 (Reference)
Urgent surgery 6.81 (4.84–9.58) <0.001 5.37 (3.74–7.69) <0.001
Surgery with intermediate to high 
cardiac risk
3.73 (2.53–5.51) <0.001 1.81 (1.16–2.81) 0.008
Surgery with hemorrhagic risk
Intermediate 2.17 (1.44–3.28) <0.001 2.10 (1.36–3.24) 0.001
High 6.80 (4.48–10.3) <0.001 4.38 (2.69–7.14) <0.001
Major adverse cardiac events
Discontinuing antiplatelet therapy 0.56 (0.29–1.07) 0.081 1.13 (0.57–2.24) 0.721
Age, per 1- y increase 1.03 (1.00–1.06) 0.087 ··· ···
Diabetes mellitus 1.79 (0.95–3.37) 0.072 ··· ···
Chronic heart failure 5.28 (2.76–10.1) <0.001 3.06 (1.53–6.13) 0.002
Chronic kidney disease 2.42 (1.23–4.75) 0.011 ··· ···
Anemia 4.17 (2.24–7.74) <0.001 2.65 (1.36–5.14) 0.004
Use of β- blocker 0.44 (0.22–0.88) 0.020 0.40 (0.20–0.80) 0.010
High- risk PCI 2.55 (1.37–4.75) 0.003 2.28 (1.21–4.28) 0.011
Duration between PCI and surgery, mo
<6 3.17 (1.61–6.21) 0.001 1.99 (0.98–4.01) 0.056
6 to <12 1.47 (0.58–3.69) 0.417 1.36 (0.54–3.43) 0.517
≥12 (Reference) (Reference)
Urgent surgery 12.6 (6.74–23.6) <0.001 10.2 (5.35–19.5) <0.001
Surgery with intermediate to high 
cardiac risk
4.30 (2.05–9.03) <0.001 3.81 (1.79–8.13) 0.001
Major bleeding
Discontinuing antiplatelet therapy 1.11 (0.75–1.66) 0.597 1.22 (0.80–1.87) 0.349
Age, per 1- y increase 1.02 (1.00–1.04) 0.033 ··· ···
BMI, per 1- kg/m2 increase 0.92 (0.86–0.98) 0.008 0.94 (0.88–1.00) 0.054
Anemia 2.58 (1.71–3.88) <0.001 2.33 (1.54–3.54) <0.001
Prior cerebrovascular attack 1.69 (1.00–2.86) 0.049 ··· ···
DAPT before surgery 1.77 (1.18–2.64) 0.006 ··· ···
Urgent surgery 5.43 (3.59–8.19) <0.001 4.21 (2.72–6.51) <0.001
 (Continued)
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PCI characteristics, or time interval since PCI would 
concern the decision of continuing APT. However, pa-
tients receiving potent APT with P2Y12 inhibitors, which 
may be required for more powerful prevention against 
ischemic events, were discouraged from continuing APT 
during NCS. The discrepancy between the scopes of 
Predictors
Univariate Analysis Multivariate Analysis
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Surgery with hemorrhagic risk
Intermediate 2.71 (1.59–4.59) <0.001 2.68 (1.57–4.58) <0.001
High 11.5 (6.94–19.0) <0.001 9.21 (5.49–15.5) <0.001
BMI indicates body mass index; DAPT, dual antiplatelet therapy; and PCI, percutaneous coronary intervention.
Table 2. Continued
Figure 3. Forest plot of adjusted hazard ratio of discontinuing antiplatelet therapy for net adverse clinical event in subgroup 
analysis.
Cox proportional hazards model for net adverse clinical event was adjusted with diabetes mellitus, chronic heart failure, chronic 
kidney disease, anemia, high- risk PCI, preoperative use of antiplatelet therapy and β- blocker, urgent surgery, and surgical risk for 
cardiac and hemorrhagic risk. Center dots and whiskers indicate hazard ratios and 95% CIs, respectively. DAPT indicates dual 
antiplatelet therapy; and PCI, percutaneous coronary intervention.
J Am Heart Assoc. 2020;9:e016218. DOI: 10.1161/JAHA.119.016218 10
Kim et al Antiplatelet Therapy During Noncardiac Surgery
APT during the post- PCI period and during the perioper-
ative period should be carefully taken on board.
Our 49% incidence of discontinuing APT during 
NCS is higher than previously reported rates. In a re-
cent observation study with 847 patients receiving cor-
onary stents,21 only 96 (11%) received no antiplatelet 
therapy during NCS. However, the study included pa-
tients with all stent types, including bare- metal stents 
and first- generation DES. It also claimed harmfulness 
of DAPT, which led to a higher likelihood of bleeding 
(odds ratio, 4.00; P=0.031) without reduction in isch-
emic events (odds ratio, 1.83; P=0.32). The incidence 
of MACEs was similar between antiplatelet (mostly as-
pirin) monotherapy (3.0%), and no antiplatelet therapy 
(3.1%), as was the risk of bleeding.21
Our incidences of MACEs (40 events, 1.1%) and 
MI (13 events, 0.4%) were lower than those previously 
reported. POISE- 2 reported 30- day MI after NCS in 
6.1% of patients without PCI and 8.1% of patients with 
PCI,6,7 and observational studies reported in- hospital 
or 30- day MACEs in 3.8% to 5.4% of patients after 
NCS.8,21–23 However, most previous studies enrolled 
small numbers of patients with PCI8 and included pa-
tients with primarily previous generation DES. Our low 
percentage of ischemic events may be at least par-
tially attributed to the use of second- generation DES. It 
may also relate to our lack of routinely measuring car-
diac enzyme levels, which are associated with 30- day 
mortality and elevated ≈10% after NCS.24 However, 
participating sites in our study usually recommend 
routine measurement of postoperative cardiac enzyme 
and ECG after surgery with cardiac risk, and clinically 
relevant myocardial infarction requiring any further at-
tention or further management by physician were in-
cluded in our study.
It is uncertain how effectively short- term discon-
tinuation of APT would withdraw platelet inhibition in 
patients undergoing NCS. Interestingly, we found that 
continuation of APT was very similar to short- term dis-
continuation of APT (for 1–3 days) regarding both isch-
emic and hemorrhagic risk during the perioperative 
period. Instead, prolonged discontinuation (≥9  days), 
which would reflect almost complete withdrawal of 
platelet inhibition, was independently associated with 
MACE. The finding may suggest the hypothesis that 
sustained and complete withdrawal of platelet inhibi-
tion would be still harmful during NCS. Further investi-
gation is warranted.
Limitations
Because of the observational manner, bias may have 
existed regarding the decision to discontinue APT. 
Although differences in covariates were adjusted 
for when comparing patterns of perioperative APT, 
undetected confounders may have affected our 
results. One- way decision or randomized assignment 
of APT was not appropriate because our population 
included a wide spectrum of clinical, surgical, and 
PCI- related factors. Another limitation was the lower 
incidence of MACEs than in previous studies, the 
potential reasons for which are discussed above. 
Furthermore, although our study included the largest 
number of patients with second- generation DES, 
the number was insufficient to allow comparisons of 
individual outcomes. As this study was conducted in 
Korea, the results may not be generalizable to other 
clinical settings. This study is thereby considered 
hypothesis generating, and further investigations are 
necessary to determine whether discontinuing APT 
Figure 4. Cumulative incidence of perioperative adverse events comparing continuation of antiplatelet therapy vs different 
durations of antiplatelet therapy discontinuation. 
Duration of 4 to 8 days was determined to be associated with the lowest risk for net adverse clinical event by generalized additive 
model. Discontinuation for 1 to 3, 4 to 8, and ≥9 days was compared with continuing antiplatelet therapy in regard to net adverse 
clinical event (A), major adverse cardiac event (B), and major bleeding (C).
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during NCS is appropriate for patients with second- 
generation DES. There would be the possibility of 
inflated type 1 errors since adjustments of multiplicity 
under a predefined protocol were not applied. 
However, the adjustment would not be necessary 
because of the exploratory nature of the study.
CONCLUSIONS
APT was discontinued preoperatively in almost half of 
patients undergoing PCI with second- generation DES 
by consensus decision before NCS. Our explorative 
analysis found that discontinuing APT may not be 
associated with increased risk of NACE, MACE, and 
major bleeding unless it is extended beyond 8  days. 
Discontinuing APT may be better in terms of NACE 
or MACE in selected patients awaiting certain types 
of surgery such as intra- abdominal surgery in which 
it would be more impactful for limiting hemorrhagic 
risk. Our findings may not imply causality and should 
be carefully interpreted considering the retrospective 
manner.
ARTICLE INFORMATION
Received February 13, 2020; accepted April 23, 2020.
Affiliations
From the Department of Cardiology, Ewha Womans University College of 
Medicine Seoul Hospital, Seoul, Korea (C.K., S.S.); Division of Cardiology, 
Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei 
University College of Medicine, Seoul, Korea (C.K., J.-S.K., H.K., S.-J.H., D.-
H.S., C.-M.A., B.-K.K., Y.-G.K., D.C., M.-K.H., Y.J.); Division of Cardiology, 
Department of Internal Medicine, Wonju Severance Christian Hospital, 
Yonsei University Wonju College of Medicine, Wonju, Korea (S.G.A.); Division 
of Cardiovascular Medicine, Department of Internal Medicine, Dankook 
University Hospital, Dankook University College of Medicine, Cheonan, Korea 
(S.C.); Division of Cardiology, Yongin Severance Hospital, Yonsei University 
College of Medicine, Gyeonggi-do, Korea (O.-H.L.); Division of Cardiology, 
National Health Insurance Service Ilsan Hospital, Goyang, Korea (J.-K.P., 
S.-J.O.); Department of Cardiology, CHA Bundang Medical Center, CHA 
University, Seongnam, Korea (J.Y.M.); Cardiovascular & Arrhythmia Center, 
Chung-Ang University Hospital, Chung-Ang University College of Medicine, 
Seoul, Korea (H.W.); Department of Cardiology, Myongji Hospital, Hanyang 
University College of Medicine, Goyang, Korea (Y.S.,Y.-H.C.); Division of 
Cardiology, Kangnam Sacred Heart Hospital, Hallym University Medical 
Center, Seoul, Korea (J.R.C.); Division of Cardiology, Gangnam Severance 
Hospital, Yonsei University College of Medicine, Seoul, Korea (B.-K.L.).
Sources of Funding
This research was supported by a grant of the Korea Health Technology 
R&D Project through the Korea Health Industry Development Institute 
(KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (No: 
HI15C1277), a grant from the National Research Foundation of Korea (NRF) 
grant, funded by the Korean Government (MSIT) (No. 2017R1A2B2003191), 
the Ministry of Science & ICT (2017M3A9E9073585) and the Cardiovascular 








 1. Philip F, Agarwal S, Bunte MC, Goel SS, Tuzcu EM, Ellis S, Kapadia 
SR. Stent thrombosis with second- generation drug- eluting stents 
compared with bare- metal stents: network meta- analysis of primary 
percutaneous coronary intervention trials in ST- segment–elevation 
myocardial infarction. Circ Cardiovasc Interv. 2014;7:49–61.
 2. Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski 
L, Waksman R, Berti S, Musumeci G, Limbruno U, et al. First- generation 
versus second- generation drug- eluting stents in current clinical practice: 
updated evidence from a comprehensive meta- analysis of randomised 
clinical trials comprising 31 379 patients. Open Heart. 2014;1:e000064.
 3. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman 
JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, 
Kane GC, et al. 2014 ACC/AHA guideline on perioperative cardiovas-
cular evaluation and management of patients undergoing noncardiac 
surgery: a report of the American College of Cardiology/American 
Heart Association Task Force on practice guidelines. Circulation. 
2014;130:e278–e333.
 4. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD, Ford 
I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, et al. 2014 ESC/
ESA guidelines on non- cardiac surgery: cardiovascular assessment 
and management: the Joint Task Force on non- cardiac surgery: car-
diovascular assessment and management of the European Society of 
Cardiology (ESC) and the European Society of Anaesthesiology (ESA). 
Eur Heart J. 2014;35:2383–2431.
 5. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, 
Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, et al. 2018 ESC/
EACTS guidelines on myocardial revascularization. Eur Heart J. 
2019;40:87–165.
 6. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello 
P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, et  al. 
Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 
2014;370:1494–1503.
 7. Graham MM, Sessler DI, Parlow JL, Biccard BM, Guyatt G, Leslie K, 
Chan MTV, Meyhoff CS, Xavier D, Sigamani A, et al. Aspirin in patients 
with previous percutaneous coronary intervention undergoing noncar-
diac surgery. Ann Intern Med. 2018;168:237–244.
 8. Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox 
TM. Risk of major adverse cardiac events following noncardiac surgery 
in patients with coronary stents. JAMA. 2013;310:1462–1472.
 9. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, 
Vandenbroucke JP. The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement: guidelines for reporting 
observational studies. Lancet. 2007;370:1453–1457.
 10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, 
Katus HA, Lindahl B, Morrow DA, Clemmensen PM, et al. Third univer-
sal definition of myocardial infarction. Circulation. 2012;126:2020–2035.
 11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, 
Steg PG, Morel MA, Mauri L, Vranckx P, et  al. Clinical end points in 
coronary stent trials: a case for standardized definitions. Circulation. 
2007;115:2344–2351.
 12. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher 
W. Definition of major bleeding in clinical investigations of antihemo-
static medicinal products in surgical patients. J Thromb Haemost. 
2010;8:202–204.
 13. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid 
A, Costa RA, Hong MK, Kim BK, Jang Y, et  al. Efficacy and safety 
of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 
2016;68:1851–1864.
 14. Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P, 
Capodanno D, Leonardi S, Lettino M, Limbruno U, et al. A multidisci-
plinary approach on the perioperative antithrombotic management of 
patients with coronary stents undergoing surgery: surgery after stent-
ing 2. JACC Cardiovasc Interv. 2018;11:417–434.
 15. Russell C, Roberts M, Williamson TG, McKercher J, Jolly SE, McNeil 
J. Clinical categorization for elective surgery in Victoria. ANZ J Surg. 
2003;73:839–842.
 16. Glance LG, Lustik SJ, Hannan EL, Osler TM, Mukamel DB, Qian F, Dick 
AW. The Surgical Mortality Probability Model: derivation and valida-
tion of a simple risk prediction rule for noncardiac surgery. Ann Surg. 
2012;255:696–702.
 17. Bewick V, Cheek L, Ball J. Statistics review 14: logistic regression. Crit 
Care. 2005;9:112–118.
J Am Heart Assoc. 2020;9:e016218. DOI: 10.1161/JAHA.119.016218 12
Kim et al Antiplatelet Therapy During Noncardiac Surgery
 18. Rizopoulos D. JM: an R package for the joint modelling of longitudinal 
and time- to- event data. J Stat Softw. 2010;35:33.
 19. Hastie T, Tibshirani R. Generalized additive models. Stat Sci. 
1986;1:297–310.
 20. White IR, Royston P, Wood AM. Multiple imputation using chained 
equations: issues and guidance for practice. Stat Med. 2011;30: 
377–399.
 21. Howell SJ, Hoeks SE, West RM, Wheatcroft SB, Hoeft A. Prospective 
observational cohort study of the association between antiplatelet ther-
apy, bleeding and thrombosis in patients with coronary stents undergo-
ing noncardiac surgery. Br J Anaesth. 2019;122:170–179.
 22. Rabbitts JA, Nuttall GA, Brown MJ, Hanson AC, Oliver WC, Holmes 
DR, Rihal CS. Cardiac risk of noncardiac surgery after percutane-
ous coronary intervention with drug- eluting stents. Anesthesiology. 
2008;109:596–604.
 23. Albaladejo P, Marret E, Samama CM, Collet JP, Abhay K, Loutrel O, 
Charbonneau H, Jaber S, Thoret S, Bosson JL, et al. Non- cardiac surgery in 
patients with coronary stents: the RECO study. Heart. 2011;97:1566–1572.
 24. Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar 
JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, et al. Association be-
tween postoperative troponin levels and 30- day mortality among pa-






Definition of major bleeding according to ISTH criteria 
Any one of the followings: 
1. Fatal bleeding, and/or 
2. Bleeding that is symptomatic and occurs in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, pericardial, in a non-operated joint, or 
intramuscular with compartment syndrome, assessed in consultation with the surgeon, 
and/or 
3. Extrasurgical site bleeding causing a fall in hemoglobin level of ≥2.0 g/dL, or leading 
to transfusion of ≥2 units of whole blood or red cells, with temporal association within 
24 to 48 h to the bleeding 
4. Surgical site bleeding that requires a second intervention or a hemarthrosis of sufficient 
size as to interfere with rehabilitation by delaying mobilization or delayed wound 
healing, resulting in prolonged hospitalization or a deep wound infection 
5. Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to 
cause hemodynamic instability, as assessed by the surgeon. There should be an 
associate fall in hemoglobin level of at least ≥2.0 g/dL, or transfusion, indicated by the 
bleeding, of ≥2 units of whole blood or red cells, with temporal association within 24 
h to the bleeding. 
6. The period for collection of these data is from start of surgery until five half-lives after 
the last dose of the drug with the longest half-life and with the longest treatment period 
(in case of unequal active treatment durations).
Table S1. Comparison of the Akaike Information Criterion (AIC) of the Cox proportional 






(Continuing APT) + (age) + (BMI) + (DM) + (CHF) + (CKD) + 
(anemia) + (preoperative APT) + (preoperative beta blocker) + 
(high risk PCI) + (duration between PCI and surgery) + 
(urgent surgery) + (surgical risk for cardiac event) + 
(surgical risk for hemorrhagic event) 
17 2017.70 
(Continuing APT) + (age) + (BMI) + (DM) + (CHF) + (CKD) + 
(anemia) + (preoperative APT) + (preoperative beta blocker) + 
(high risk PCI) + (urgent surgery) + 
(surgical risk for cardiac event) + 
(surgical risk for hemorrhagic event) 
15 2014.32 
(Continuing APT) + (age) + (DM) + (CHF) + (CKD) + 
(anemia) + (preoperative APT) + (preoperative beta blocker) + 
(high risk PCI) + (urgent surgery) + 
(surgical risk for cardiac event) + 
(surgical risk for hemorrhagic event) 
14 2013.52 
(Continuing APT) + (DM) + (CHF) + (CKD) + (anemia) + 
(preoperative APT) + (preoperative beta blocker) + 
(high risk PCI) + (urgent surgery) + 
(surgical risk for cardiac event) + 
(surgical risk for hemorrhagic event) 
13 2013.26 
APT = antiplatelet therapy, BMI = body mass index, CHF = congestive heart failure, CKD = 
chronic kidney disease, DM = diabetes mellitus, PCI = percutaneous coronary intervention 
  
Table S2. Comparison of the Akaike Information Criterion (AIC) of the Cox proportional 






(Continuing APT) + (age) + (DM) + (CHF) + (CKD) + 
(anemia) + (preoperative beta blocker) + (high risk PCI) + 
(duration between PCI and surgery) + (urgent surgery) + 
(surgical risk for cardiac event) 
12 567.90 
(Continuing APT) + (age) + (DM) + (CHF) + (anemia) + 
(preoperative beta blocker) + (high risk PCI) + 
(duration between PCI and surgery) + (urgent surgery) + 
(surgical risk for cardiac event) 
11 566.55 
(Continuing APT) + (DM) + (CHF) + (anemia) + 
(preoperative beta blocker) + (high risk PCI) + 
(duration between PCI and surgery) + (urgent surgery) + 
(surgical risk for cardiac event) 
10 565.54 
(Continuing APT) + (CHF) + (anemia) + 
(preoperative beta blocker) + (high risk PCI) + 
(duration between PCI and surgery) + (urgent surgery) + 
(surgical risk for cardiac event) 
9 565.46 
APT = antiplatelet therapy, CHF = congestive heart failure, CKD = chronic kidney disease, 
DM = diabetes mellitus, PCI = percutaneous coronary intervention 
  
Table S3. Comparison of the Akaike Information Criterion (AIC) of the Cox proportional 






(Continuing APT) + (age) + (BMI) + (anemia) + (CVA) + 
(preoperative APT) + (urgent surgery) + 
(surgical risk for hemorrhagic event) 
10 1452.60 
(Continuing APT) + (BMI) + (anemia) + (CVA) + 
(preoperative APT) + (urgent surgery) + 
(surgical risk for hemorrhagic event) 
9 1450.87 
(Continuing APT) + (BMI) + (anemia) + (preoperative APT) + 
(urgent surgery) + (surgical risk for hemorrhagic event) 
8 1449.46 
(Continuing APT) + (BMI) + (anemia) + (urgent surgery) + 
(surgical risk for hemorrhagic event) 
6 1448.13 
APT = antiplatelet therapy, BMI = body mass index, CVA = cerebrovascular attack. 
  
Table S4. Independent factors for discontinuing antiplatelet therapy before non–cardiac 
surgery determined by multivariate logistic regression model. 
Covariates Odds ratio 95% confidence interval 
P–
value 
Female 1.28 1.10–1.49 0.002 
Chronic kidney disease 0.52 0.42–0.64 <0.001 
Preoperative antiplatelet therapy    
Aspirin monotherapy (Reference) 
P2Y12 inhibitor monotherapy 1.67 1.35–2.08 <0.001 
Dual antiplatelet therapy 1.25 1.05–1.49 0.014 
Beta–blocker 1.24 1.07–1.44 0.004 
RAS inhibitor 1.31 1.13–1.52 <0.001 
Diagnosis at revascularization    
Stable angina (Reference) 
Unstable angina 1.55 1.31–1.85 <0.001 
Myocardial infarction 1.41 1.19–1.68 <0.001 
High risk PCI 0.80 0.68–0.95 0.009 
Duration from PCI, mo    
<6 0.31 0.25-0.38 <0.001 
6–<12  0.68 0.55-0.84 <0.001 
≥12 (Reference) 
Urgent surgery 0.23 0.18–0.30 <0.001 
Surgery with intermediate to high 
cardiac risk 
1.37 1.16–1.61 <0.001 
Surgery with high hemorrhage risk 2.17 1.65–2.87 <0.001 
The multivariate logistic regression model was adjusted covariated listed on the table. P-value 
for McFadden’s R2 test was 0.110 indicating that the overall model fit is good. Likelihood ratio 
tests between the model versus the reduce model by eliminating each single covariate indicated 
a better goodness of fit.











Patients, N 843 250 739 1,750  
Age, y 69 (61–75) 69 (61–75) 69 (61–75) 69 (61–75) .05 
Male 599 (71) 167 (67) 516 (70) 1,120 (64) .001 
BMI, kg/m2* 24.4 (22.4–26.5) 24.7 (22.9–26.8) 23.9 (21.9–26.2) 24.4 (22.5–26.7) .001 
Comorbidity      
Hypertension 623 (74) 181 (72) 580 (78) 1,304 (75) .09 
Diabetes mellitus 349 (41) 118 (47) 404 (55) 768 (44) <.001 
Chronic heart failure 72 (9) 20 (8) 100 (14) 145 (8) <.001 
Chronic kidney disease 109 (13) 50 (20) 206 (28) 182 (10) <.001 
Prior cerebrovascular attack 86 (10) 34 (14) 98 (13) 184 (11) .10 
Anemia* 137 (16) 50 (20) 195 (26) 308 (18) <.001 
Preoperative medication      
Antiplatelet therapy     <.001 
Monotherapy      
Aspirin 627 (74) 0 (0) 0 (0) 610 (35)  
Clopidogrel 0 (0) 215 (86) 0 (0) 336 (19)  
Ticagrelor 0 (0) 6 (2) 0 (0) 2 (0.1)  
Prasugrel 0 (0) 0 (0) 0 (0) 1 (0.1)  
Others 0 (0) 0 (0) 0 (0) 5 (0.3)  
Dual therapy 216 (26) 29 (12) 739 (100) 796 (45)  
Duration of discontinuation 
before surgery, d 
– – – 5 (4–7) <.001 
Oral anticoagulant 5 (1) 0 (0.0) 1 (0) 12 (1) .21 
Beta-blocker 345 (41) 98 (39) 359 (49) 853 (49) <.001 
Calcium channel blocker 254 (30) 79 (32) 232 (31) 576 (33) .54 
RAS inhibitor 358 (42) 106 (42) 379 (51) 926 (53) <.001 
Percutaneous coronary intervention      
Diagnosis at revascularization     <.001 
Stable angina 437 (52) 131 (52) 325 (44) 708 (40)  
Unstable angina 211 (25) 50 (20) 182 (25) 547 (31)  
Myocardial infarction 195 (23) 69 (28) 232 (31) 495 (28)  
Stented vessel      
Left main 64 (8) 17 (7) 52 (7) 75 (4) .002 
Left anterior descending artery 518 (61) 153 (61) 436 (59) 1095 (63) .42 
Left circumflex artery 219 (26) 61 (24) 182 (25) 466 (27) .71 
Right coronary artery 277 (33) 94 (38) 270 (37) 621 (35) .35 
Type of DES      
Durable polymer 547 (65) 161 (64) 502 (68) 1353 (77) <.001 
Bioresorbable polymer 267 (32) 101 (40) 250 (34) 409 (23) <.001 
Polymer-free 61 (7) 1 (0) 8 (1) 18 (1) <.001 
Number of stents     .003 
1 501 (59) 136 (54) 450 (61) 1036 (59)  
2 217 (26) 64 (26) 172 (23) 501 (29)  
≥3 125 (15) 50 (20) 117 (16) 213 (12)  
Maximum stent diameter, mm*     .004 
Total stent length, mm* 30 (18–51) 32 (18–56) 29 (19–49) 30 (18–48) .58 
High risk PCI 202 (24) 81 (32) 305 (41) 450 (26) <.001 
Non-cardiac surgery       
Duration from PCI, mo 24 (12–5) 27 (15–48) 7 (2–15) 23 (12–41) <.001 
Urgent surgery 114 (14) 38 (15) 129 (17) 88 (5) <.001 
Risk of cardiac event     <.001 
Low (<1%) 479 (57) 148 (59) 455 (62) 892 (51)  
Intermediate to high (≥1%) 364 (43) 102 (41) 284 (38) 858 (49)  
Risk of hemorrhage     <.001 
Low 516 (61) 172 (69) 580 (78) 896 (51)  
Intermediate to high 247 (29) 59 (24) 119 (16) 654 (37)  
High 80 (9) 19 (8) 40 (5) 200 (11)  
Type     <.001 
Orthopedic 138 (16) 35 (14) 113 (15) 358 (20)  
Major 29 (3) 8 (3) 22 (3) 78 (4)  
Minor 99 (12) 27 (11) 91 (12) 280 (16)  
Superficial 141 (17) 45 (18) 138 (19) 301 (17)  
Ophthalmologic 165 (20) 54 (22) 184 (25) 147 (8)  
Intraabdominal 122 (14) 25 (10) 51 (7) 317 (18)  
Urologic 108 (13) 28 (11) 47 (6) 207 (12)  
Major 46 (5) 11 (4) 13 (2) 109 (6)  
Minor 62 (7) 17 (7) 34 (5) 98 (6)  
Vascular 45 (5) 28 (11) 137 (19) 37 (2)  
Spinal 54 (6) 7 (3) 21 (3) 129 (7)  
Head and neck 29 (3) 14 (6) 8 (1) 87 (5)  
Intrathoracic 12 (1) 2 (1) 12 (2) 37 (2)  
Gynecologic 6 (1) 3 (1) 3 (0) 46 (3)  
Intracranial 19 (2) 5 (2) 25 (3) 65 (4)  
Breast 4 (0) 2 (1) 0 (0.0) 14 (1)  
Transplantation 10 (1) 2 (1) 0 (0.0) 5 (0)  
 
  
*These comparisons were performed among patients without missing values (values were missing for hemoglobin in 517 patients, BMI in 77 
patients, stent diameter in 4 patients, and total stent length in 3 patients).  
BMI = body mass index, DAPT = dual antiplatelet therapy, DES = drug-eluting stent, PCI = percutaneous coronary intervention, RAS = renin-
angiotensin system.







Net adverse clinical event 76 (4.1) 59 (3.4) 0.257 
Major adverse cardiac event 26 (1.4) 14 (0.8) 0.109 
Major bleeding 47 (2.6) 50 (2.9) 0.664 
Death 40 (2.2) 24 (1.4) 0.088 
Cardiac 20 (1.1) 10 (0.6) 0.127 
Noncardiac 20 (1.1) 14 (0.8) 0.467 
Associated with bleeding 13 (0.7) 18 (1.0) 0.395 
Myocardial infarction 9 (0.5) 4 (0.2) 0.303 
Stent thrombosis 0 (0.0) 2 (0.1) 0.459 
 














Net adverse clinical event 26 (3.1) 13 (5.2) 37 (5.0) 59 (3.4) 0.094 
Major adverse cardiac event 7 (0.8) 2 (0.8) 17 (2.3) 14 (0.8) 0.008 
Major bleeding 16 (1.9) 10 (4.0) 21 (2.8) 50 (2.9) 0.275 
Death 9 (1.1) 3 (1.2) 28 (3.8) 24 (1.4) <0.001 
Cardiac 4 (0.5) 1 (0.4) 15 (2.0) 10 (0.6) 0.001 
Noncardiac 5 (0.6) 2 (0.8) 13 (1.8) 14 (0.8) 0.080 
Associated with bleeding 2 (0.2) 1 (0.4) 10 (1.4) 18 (1.0) 0.069 
Myocardial infarction 3 (0.4) 1 (0.4) 5 (0.7) 4 (0.2) 0.408 
Stent thrombosis 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.1) 0.553 
 
Figure S1. Diagnostic plots for the proportional hazard assumption of the Cox 
models with scaled Schoenfeld residuals for each covariate against time to net 
adverse clinical event (A), major adverse cardiac event (B), and major bleeding (C). 
 
 
A. Net adverse clinical event 
 
B. Major adverse cardiac event 
 




Figure S2. Forest plot of adjusted hazard ratio of discontinuation of antiplatelet therapy 
for major adverse cardiac event in subgroup analysis. Cox proportional hazard model for 
net adverse clinical event was adjusted with chronic heart failure, anemia, high risk PCI, 
preoperative use of beta–blocker, urgent surgery and surgical risk for cardiac event. Center 
dots and whiskers indicate hazard ratios and 95% confidence intervals, respectively. CI = 




Figure S3. Forest plot of adjusted hazard ratio of discontinuing antiplatelet therapy for 
major bleeding in subgroup analysis. Cox proportional hazard model for net adverse clinical 
event was adjusted with body mass index, anemia, urgent surgery and surgical risk for 
hemorrhagic event. Center dots and whiskers indicate hazard ratios and 95% confidence 
intervals, respectively. CI = confidence interval, DAPT = dual antiplatelet therapy, PCI = 
percutaneous coronary intervention 
  
 
Figure S4. Nonparametric smoothing plot using generalized additive model of duration 
of antiplatelet therapy before non-cardaic surgery. The plot indicates that discontinuing 
antiplatelet therapy for 6 days was associated with the lowest risk of net adverse clinical event 
in patients undergoing non-cardiac surgery. Time interval from 4 to 8 days would be defined 
as optimal duration for discontinuation of antiplatelet agent before non-cardiac surgery in the 
analysis. Dashed lines and the shaded area indicate the 95% confidence intervals. The y-axis 
represents the effect of discontinuation duration on net adverse clinical event. 
  
 
Figure S5. Adjusted hazard ratio of discontinuing antiplatelet therapy for net adverse 
clinical event, major adverse cardian event and major bleeding. Center dots and whiskers 
indicate hazard ratios and 95% confidence intervals, respectively. CI = confidence interval.A.  
